Cholestatic liver disease: pathophysiology and therapeutic options

被引:84
|
作者
Hofmann, AF [1 ]
机构
[1] Univ Calif San Diego, Dept Med, Div Gastroenterol, La Jolla, CA 92093 USA
来源
LIVER | 2002年 / 22卷
关键词
bile acids; cholestasis; extracorporeal albumin dialysis; haemoperfusion; pruritus; review;
D O I
10.1034/j.1600-0676.2002.00002.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Cholestasis results from defective canalicular secretion of bile or obstruction to bile flow distal to the canaliculus. In early primary biliary cirrhosis, bile secretion continues, because of the secretory pressure of bile or because some ductules are not obstructed. With complete cholestasis, a bile acid deficiency occurs in the small intestinal lumen leading to lipid maldigestion and fat-soluble vitamin malabsorption. Bacterial proliferation, bacterial translocation to lymph nodes and endotoxemia may also occur leading to an acute phase reaction. Retention of bile acids in the hepatocyte leads to apoptosis. Accumulation of bile acids in the systemic circulation leads to pruritus, and may contribute to endothelial injury in the lungs and kidney. Early attempts to mimic hepatic excretory function by hemoperfusion over adsorbent columns were unsuccessful for a variety of reasons. Extracorporeal dialysis against albumin offers promise of a realistic albeit partial simulation of hepatic excretory function.
引用
收藏
页码:14 / 19
页数:6
相关论文
共 50 条
  • [31] Therapeutic options for nonalcoholic fatty liver disease and steatohepatitis
    Kluwe, J
    Lohse, AW
    INTERNIST, 2005, 46 (12): : 1324 - +
  • [32] Therapeutic targets for cholestatic liver injury
    Woolbright, Benjamin L.
    Jaeschke, Hartmut
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2016, 20 (04) : 463 - 475
  • [33] Cognitive deficits and psychosis in Parkinson's disease - A review of pathophysiology and therapeutic options
    Williams-Gray, Caroline H.
    Foltynie, Thomas
    Lewis, Sinion J. G.
    Barker, Roger A.
    CNS DRUGS, 2006, 20 (06) : 477 - 505
  • [34] Liver transplantation for cholestatic liver disease
    James Neuberger
    Current Treatment Options in Gastroenterology, 2003, 6 (2) : 113 - 121
  • [35] THE AGING HYPERTENSIVE KIDNEY - PATHOPHYSIOLOGY AND THERAPEUTIC OPTIONS
    BAUER, JH
    REAMS, GP
    WU, Z
    AMERICAN JOURNAL OF MEDICINE, 1991, 90 : S21 - S27
  • [36] Pathophysiology and therapeutic options for cirrhotic portal hypertension
    Guixe-Muntet, Sergi
    Quesada-Vazquez, Sergio
    Gracia-Sancho, Jordi
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (07): : 646 - 663
  • [37] Pathophysiology and therapeutic options in primary immune thrombocytopenia
    Stasi, Roberto
    BLOOD TRANSFUSION, 2011, 9 (03) : 262 - 273
  • [38] Pathophysiology and therapeutic options in osteogenesis imperfecta: an update
    Brizola, Evelise
    Felix, Temis M.
    Shapiro, Jay R.
    RESEARCH AND REPORTS IN ENDOCRINE DISORDERS, 2016, 6 : 17 - 30
  • [39] Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited
    Paumgartner, G
    Beuers, U
    HEPATOLOGY, 2002, 36 (03) : 525 - 531
  • [40] Molecular pathogenesis of chronic cholestatic liver disease: Impact on novel therapeutic approaches
    Fickert, Peter
    Stieger, Bruno
    MOLECULAR ASPECTS OF MEDICINE, 2014, 37 : 1 - 2